Overview

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status:
Completed

Trial end date:
2020-12-17

Target enrollment:

Participant gender:

Summary

This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) not eligible for transplant.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pharmacyclics LLC.

Collaborators:

Celgene Corporation
Janssen Research & Development, LLC

Treatments:

Lenalidomide
Rituximab
Thalidomide